BAKER HEART AND DIABETES INSTITUTE

Their core work

The Baker Heart and Diabetes Institute is a specialist medical research institute in Melbourne, Australia, dedicated to cardiovascular disease and diabetes — their name reflects a decades-long scientific focus on these intertwined chronic conditions. Their H2020 involvement reveals two distinct contributions: as an international clinical partner bringing Southern Hemisphere research expertise into European postdoctoral training networks, and as a participant in large-scale digital health interventions targeting diabetes and hypertension in community settings. Their real-world work spans bench-to-bedside translational research, community-based screening programmes, and the clinical validation of mHealth tools designed to support self-management of chronic metabolic and cardiovascular conditions. As one of few non-European institutions in these consortia, they bring access to Australian patient cohorts, clinical trial infrastructure, and public health perspectives that differ meaningfully from the EU norm.

What they specialise in

How they've shifted over time

Their early H2020 engagement (WIRL, 2017–2021) was institutional rather than thematic — they joined as an international partner in a researcher leadership programme, contributing to cross-sectoral postdoctoral training and global mobility networks rather than advancing a specific disease research agenda. By 2021, their second project (DigiCare4You) marks a clear pivot to applied translational work: digital tools, community screening, lifestyle intervention, and chronic disease self-management are now the explicit focus. The shift is from training infrastructure to technology-enabled clinical delivery — suggesting the institute is increasingly engaged in the implementation end of the research pipeline, not just knowledge generation.

The institute is moving toward real-world deployment of digital health tools for diabetes and cardiovascular risk management, making them a relevant partner for consortia combining clinical validation, patient-facing technology, and community health scaling.

How they like to work

Baker has not coordinated any H2020 project — they consistently join as partner or participant, contributing specialist clinical expertise within larger international consortia rather than driving administrative leadership. Despite only two projects, they have accumulated 58 unique consortium partners across 15 countries, which signals participation in genuinely large multi-partner projects where their role is likely focused and well-defined. This suggests they are most valuable as a specialist contributor — providing clinical access, patient data, or domain authority — rather than as a project management hub.

Despite only two H2020 projects, Baker has worked with 58 distinct partner organisations across 15 countries — a notably broad network for such limited participation, driven by involvement in large multi-partner consortia. Their geographic footprint is genuinely intercontinental: an Australian institute embedded in European and globally collaborative research projects.

What sets them apart

Baker is one of the very few non-European, non-associated-country institutions in the H2020 corpus, which immediately marks them as an unusual and potentially high-value partner for any consortium seeking international clinical validation or access to Southern Hemisphere patient populations. Their institutional focus — where cardiology and diabetology are structurally integrated — is rare: most research institutions treat these as separate departments, while Baker's entire scientific identity is built around their co-occurrence. For a consortium working on chronic metabolic disease, digital self-management, or cardiovascular prevention, they bring both clinical credibility and a genuinely different epidemiological context from Australia.

Highlights from their portfolio

• DigiCare4You
  A current (2021–2026) large-scale EU initiative developing integrated digital solutions for diabetes and hypertension management in community and primary care settings — directly aligned with Baker's core clinical mission and their most substantive EU engagement to date.
• WIRL
  Baker's entry into H2020 as an international partner in a Warwick-led MSCA-COFUND leadership programme demonstrates their willingness to anchor cross-sectoral, multi-country researcher development networks — a different capability profile from their disease-specific work.